Express Mail Label No.: E 1847031US
Date of Deposit: February 5, 2001

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

FEB 20 2001

APPLICANTS:

Lee et al.

ASSIGNEE:

President and Fellows of Harvard College

ERIAL NUMBER:

09/503,596

**EXAMINER:** 

M. Schmidt

FILING DATE:

February 11, 2000

ART UNIT:

1635

CENTER 1600/2900

For:

INHIBITING FORMATION OF ATHEROSCLEROTIC LESIONS

February 5, 2001 Boston, Massachusetts

Assistant Commissioner for Patents Washington, D.C. 20231

## STATEMENT IN SUPPORT OF COMPUTER READABLE FORM SUBMISSION UNDER 37 C.F.R. § 1.821(f)

Sir:

I hereby state that the content of the paper and computer readable forms of the Sequence Listing, submitted in the above-identified application in accordance with 37 C.F.R. § 1.821(c) and 1.821(e), respectively, are the same.

Respectfully submitted

Ivor R. Elrify, Reg. No.! 39/529 Ingrid A. Beattie, Reg. No. 42,306 David E. Johnson, Reg. No. 41,874

Attorneys for Applicants c/o MINTZ, LEVIN

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241

TRADOCS:1433606.1(%Q6#01!.DOC)

Applications CONTAINING

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other:
Applicant Must Provide:
An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For questions regarding compliance to these requirements, please contact:
For Rules Interpretation, call (703) 308-4216
For CRF Submission Help, call (703) 308-4212
Patentln Software Program Support (SIRA)  Technical Assistance
To Purchase Patentin Software703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

Date of Deposit: February 5, 2001

Attorney Docket No. 21509-042

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Lee et al.

ASSIGNEE:

President and Fellows of Harvard College

ERIAL NUMBER:

09/503,596

**EXAMINER:** 

M. Schmidt

FILING DATE:

February 11, 2000

ART UNIT:

1635

For:

INHIBITING FORMATION OF ATHEROSCLEROTIC LESIONS

February 5, 2001

Boston, Massachusetts

Assistant Commissioner for Patents Washington, D.C. 20231

## RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE LISTING REQUIREMENTS

In response to the Notice to Comply with Sequence Listing Requirements, mailed December 4, 2000, in the above-identified application, Applicants submit a substitute paper copy, and a computer readable form of the Sequence Listing. Also enclosed are a Preliminary Amendment, a Statement in Support of Computer Readable Form Submission, and a copy of the Notice to Comply with Requirements. Applicants have filed concurrently herewith a petition for a one-month extension of time, along with a check to cover the \$110.00 extension fee pursuant to C.F.R. § 1.17 (a)(1). With the extension, the response is due on or before February 5, 2001.

Please charge any additional fees that may be due, or credit any overpayment to Deposit Account

No. 50-0311, Reference No. 21509-042.

Respectfully submitted,

Ivor R. Efrifi, Reg./No.: 39,529

Ingrid A. Beattie, Reg. No. 42,306 David E. Johnson/Reg. No. 41,874

Attorneys for Applicants

c/o MINTZ, LEVIN

One Financial Center
Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241

TRADOCS:1433585.1(%Q5T01!.DOC)